Cited by 3,114T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Molecular mechanisms of T cell co-stimulation and co-inhibition

Open access

Chen, Lieping, Flies, Dallas B.·2013·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Co-stimulatory and co-inhibitory receptors have a pivotal role in T cell biology, as they determine the functional outcome of T cell receptor (TCR) signalling. The classic definition of T cell co-stimulation continues to evolve through the identification of new co-stimulatory and co-inhibitory receptors, the biochemical characterization of their downstream signalling events and the delineation of their immunological functions. Notably, it has been recently appreciated that co-stimulatory and co-inhibitory receptors display great diversity in expression, structure and function, and that their functions are largely context dependent. Here, we focus on some of these emerging concepts and review the mechanisms through which T cell activation, differentiation and function is controlled by co-stimulatory and co-inhibitory receptors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nri3405

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860

Flagged first, then by citations

Show all 135 references

Research works printed but not linked: 1

Lafferty, K. J. & Cunningham, A. J. A. New analysis of allogeneic interactions. J. Immunol. 112, 436–437 (1975). Lafferty and Cunningham extended the Bretscher and Cohn two-signal model to suggest that T cells require two signals for activation.

Sorted by citations

Items 601–700 of 1,003

Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
Roth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 66
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
Porcu, M., Silva, P. D., Solinas, C., Battaglia, A., Schena, M., Scartozzi, M., Bron, D., Suri, J. S., Willard-Gallo, K. E., Sangiolo, D., et al. (2019) · Cancers · doi:10.3390/cancers11030305 · Cited by 64
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiang, X. J., Yu, P., Long, D., Liao, X.-L., Zhang, S., You, X., Zhong, J., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.23580 · Cited by 64
LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
Seifert, L., Plesca, I., Müller, L., Sommer, U. J., Heiduk, M., von Renesse, J., Digomann, D., Glück, J., Klimová, A., Weitz, J., et al. (2021) · Cancers · doi:10.3390/cancers13061297 · Cited by 61
Cancer immunomodulation using bispecific aptamers
Thomas, B. J., Porciani, D., & Burke, D. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.008 · Cited by 62
Metabolic and Immune Crosstalk in Cardiovascular Disease
Mohanta, S. K., Heron, C., Klaus‐Bergmann, A., Horstmann, H., Bråkenhielm, E., Giannarelli, C., Habenicht, A. J. R., Gerhardt, H., & Weber, C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325496 · Cited by 68
“192 This proliferation promotes differentiation of antigen-specific T cells into effector and memory subsets.”
Mitochondrial Metabolism in T Cell Activation and Senescence: A Mini-Review
Ron‐Harel, N., Sharpe, A. H., & Haigis, M. C. (2014) · Gerontology · doi:10.1159/000362502 · Cited by 66
Impact of host genetic polymorphisms on vaccine induced antibody response
Linnik, J., & Egli, A. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1119345 · Cited by 65
T Cells Going Innate
Seyda, M., Elkhal, A., Quante, M., Falk, C. S., & Tullius, S. G. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.06.004 · Cited by 63
Innate Immune Responses in Fish: Antigen Presenting Cells and Professional Phagocytes
Kordon, A. O., Karsi, A., & Pinchuk, L. M. (2018) · Turkish Journal of Fisheries and Aquatic Sciences · doi:10.4194/1303-2712-v18_9_11 · Cited by 67
Social Networking of Group Two Innate Lymphoid Cells in Allergy and Asthma
Hurrell, B. P., Shafiei-Jahani, P., & Akbari, O. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02694 · Cited by 62
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
Zhang, X., Luo, M., Dastagir, S. R., Nixon, M. J., Khamhoung, A., Schmidt, A., Lee, A., Subbiah, N., McLaughlin, D. C., Moore, C. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22898-3 · Cited by 64
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome
Chien, K. S., Kim, K., Nogueras‐González, G. M., Borthakur, G. M., Naqvi, K., Daver, N. G., Bravo, G. M., Cortes, J. E., Dinardo, C. D., Jabbour, E. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17689 · Cited by 62
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
“260 267 At this stage, costimulatory signals (e.g., CD28-CD80/86) and inhibitory signals (e.g., CTLA-4) are balanced to regulate T cell activation and prevent excessive immune responses.”
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Zhang, D., Goldberg, M. V., & Chiu, M. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.757773 · Cited by 68
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia
Oda, S. K., Daman, A. W., Garcia, N. M., Wagener, F. D., Schmitt, T. M., Tan, X., Chapuis, A. G., & Greenberg, P. D. (2017) · Blood · doi:10.1182/blood-2017-04-777052 · Cited by 62
Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function
Imanishi, T., Unno, M., Kobayashi, W., Yoneda, N., Matsuda, S., Ikeda, K., Hoshii, T., Hirao, A., Miyake, K., Barber, G. N., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800282 · Cited by 62
Phosphatidylserine binding directly regulates TIM-3 function
Smith, C. M., Li, A., Krishnamurthy, N., & Lemmon, M. A. (2021) · Biochemical Journal · doi:10.1042/bcj20210425 · Cited by 61
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Oda, S. K., Anderson, K. G., Ravikumar, P., Bonson, P., Garcia, N. M., Jenkins, C. M., Zhuang, S., Daman, A. W., Chiu, E. Y., Bates, B. M., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191166 · Cited by 61
Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients
Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A., Kiros, S. T., Mencarini, J., Zammarchi, L., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048915 · Cited by 61
OX40L–OX40 Signaling in Atopic Dermatitis
Furue, M., & Furue, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122578 · Cited by 67
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy
Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Zhao, X., Yu, Y., Zhang, H., Xu, F., & Tian, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02068-5 · Cited by 64
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
Wachsmann, T. L. A., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., Meeuwsen, M. H., van Diest, E., Leusen, J. H. W., Kuball, J. H. E., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2033528 · Cited by 66
PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury
Gao, X., Li, W., Syed, F., Yuan, F., Li, P., & Yu, Q. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02398-x · Cited by 62
High ratio of programmed cell death protein 1 (PD-1)+/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy
Lim, Y. J., Koh, J., Kim, K., Chie, E. K., Kim, B., Lee, K. B., Jang, J., Kim, S., Oh, D., Bang, Y., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.07.003 · Cited by 61
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjö, M., Marsh, H. C., & Keler, T. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0080-2 · Cited by 64
Specific CD8+T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis
Moreno-Cubero, E., & Larrubia, J. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6469 · Cited by 60
Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma
Elsegood, C. L., Tirnitz‐Parker, J. E. E., Olynyk, J. K., & Yeoh, G. C. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.47 · Cited by 63
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Peptide-based targeting of immunosuppressive cells in cancer
Trac, N. T., & Chung, E. J. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.01.006 · Cited by 60
speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing
Castellanos-Rueda, R., Roberto, R. B. D., Bieberich, F., Schlatter, F. S., Palianina, D., Nguyen, O. T. P., Kapetanovic, E., Laubli, H. P., Hierlemann, A. R., Khanna, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34141-8 · Cited by 61
T Cell–Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses
O’Neill, R., Du, W., Mohammadpour, H., Alqassim, E., Qiu, J., Chen, G. L., McCarthy, P. L., Lee, K. P., & Cao, X. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700380 · Cited by 60
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 60
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Musacchio, L., Boccia, S. M., Caruso, G., Santangelo, G., Fischetti, M., Tomao, F., Perniola, G., Palaia, I., Muzii, L., Pignata, S., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061721 · Cited by 61
Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation
Toulmin, S. A., Bhadiadra, C., Paris, A. J., Lin, J. H., Katzen, J. B., Basil, M. C., Morrisey, E. E., Worthen, G. S., & Eisenlohr, L. C. (2021) · Nature Communications · doi:10.1038/s41467-021-23619-6 · Cited by 60
Clinical significance of tumor‐infiltrating immune cells focusing on BTLA and Cbl‐b in patients with gallbladder cancer
Oguro, S., Ino, Y., Shimada, K., Hatanaka, Y., Matsuno, Y., Esaki, M., Nara, S., Kishi, Y., Kosuge, T., & Hiraoka, N. (2015) · Cancer Science · doi:10.1111/cas.12825 · Cited by 62
Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells
Kozela, E., Juknat, A., Kaushansky, N., Ben‐Nun, A., Coppola, G., & Vogel, Z. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0273-0 · Cited by 59
Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars
Ou, Y., Webb, J. A., O'Brien, C. M., Pence, I. J., Lin, E. C., Paul, E. P., Cole, D., Ou, B. S., Lapierre-Landry, M., DeLapp, R. C., et al. (2018) · Nanoscale · doi:10.1039/c8nr01478g · Cited by 59
Adaptive Immune Responses Contribute to Post-ischemic Cardiac Remodeling
Santos‐Zas, I., Lemarie, J., Tedgui, A., & Ait‐Oufella, H. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00198 · Cited by 61
Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
Qin, M., Cao, Q., Wu, X., Liu, C., Zheng, S., Xie, H., Tian, Y., Xie, J., Zhao, Y., Hou, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111856 · Cited by 59
Structural insight into T cell coinhibition by PD-1H (VISTA)
Slater, B., Han, X. N., Chen, L., & Xiong, Y. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908711117 · Cited by 60
Self-citation
Update on immune checkpoint inhibitors in gynecological cancers
Heong, V. Y. M., Ngoi, N. Y. L., & Tan, D. S. P. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e20 · Cited by 59
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
Raková, J., Truxová, I., Holíček, P., Šálek, C., Hensler, M., Kašíková, L., Pasulka, J., Holubová, M., Kovář, M., Lysák, D., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1889822 · Cited by 62
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62
Glycosylation of Immune Receptors in Cancer
Sun, R., Kim, A. M. J., & Lim, S. (2021) · Cells · doi:10.3390/cells10051100 · Cited by 58
Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo
Ouyang, Y., Gao, J., Zhao, L., Lu, J., Zhong, H., Tang, H., Jin, S., Lü, Y., Li, Y., Guo, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00370 · Cited by 58
Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy
Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0887 · Cited by 57
Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy
Sharma, P., & Otto, M. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.022 · Cited by 59
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1
Lynch, J. T., Cockerill, M. J., Hitchin, J. R., Wiseman, D. H., & Somervaille, T. C. P. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.032 · Cited by 59
Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer
Chrisikos, T. T., Zhou, Y., Slone, N., Babcock, R. L., Watowich, S. S., & Li, H. S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.01.014 · Cited by 61
Innate and Adaptive Immune Responses duringListeria monocytogenesInfection
D’Orazio, S. E. F. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0065-2019 · Cited by 64
Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells
Xu, W., Wang, X., Tu, Y., Masaki, H., Tanaka, S., Onda, K., Sugiyama, K., Yamada, H., & Hirano, T. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108726 · Cited by 58
Integrating the Tumor Microenvironment into Cancer Therapy
Sanegre, S., Lucantoni, F., Burgos-Panadero, R., de la Cruz-Merino, L., Noguera, R., & Naranjo, T. Á. (2020) · Cancers · doi:10.3390/cancers12061677 · Cited by 49
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
Nouri, Y., Weinkove, R., & Perret, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003065 · Cited by 61
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Grande, E., Arranz, J. Á., Santis, M. D., Bamias, A., Kikuchi, E., del Muro, X. G., Park, S. H., Giorgi, U. D., Alekseev, B. Y., Mencinger, M., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00540-5 · Cited by 59
Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation
Celada, L. J., Rotsinger, J. E., Young, A., Shaginurova, G. I., Shelton, D. A., Hawkins, C., & Drake, W. P. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0037oc · Cited by 57
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
Horn, L. A., Ciavattone, N. G., Atkinson, R. S., Woldergerima, N., Wolf, J., Clements, V. K., Sinha, P., Poudel, M., & Ostrand‐Rosenberg, S. (2017) · Oncotarget · doi:10.18632/oncotarget.19865 · Cited by 60
A novel intracellular pool of LFA-1 is critical for asymmetric CD8+ T cell activation and differentiation
Capece, T., Walling, B. L., Lim, K., Kim, K., Bae, S., Chung, H.-L., Topham, D. J., & Kim, M. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201609072 · Cited by 56
Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways
Baer, A., Colon‐Moran, W., & Bhattarai, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-29355-0 · Cited by 56
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 60
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
Chen, X., Liu, X., Ding, X., Zhang, J., Jiang, L., Liu, S., Hou, H., Jiang, B., Cheng, L., Zhu, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828319 · Cited by 56
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Peng, Z., Li, M., Li, H., & Gao, Q. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103666 · Cited by 57
Components, Formulations, Deliveries, and Combinations of Tumor Vaccines
Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 57
The effects of microbiota-derived short-chain fatty acids on T lymphocytes: From autoimmune diseases to cancer
Saadh, M. J., Allela, O. Q. B., Ballal, S., Mahdi, M. S., Chahar, M., Verma, R., Al-Hussein, R. K. A., Adil, M., Jawad, M. J., & Al-Nuaimi, A. M. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152398 · Cited by 65
Induction and stability of the anergic phenotype in T cells
Valdor, R., & Macián, F. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.010 · Cited by 58
The Adipocyte and Adaptive Immunity
Song, J., & Deng, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593058 · Cited by 50
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas
Wang, Y., Wu, L., Tian, C., & Zhang, Y. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3176-6 · Cited by 56
Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions
Aljabali, A. A. A., Obeid, M. A., Gammoh, O., El‐Tanani, M., Mishra, V. K., Mishra, Y., Kapre, S., Palakurthi, S. S., Hassan, S. S., Nawn, D., et al. (2024) · Cancers · doi:10.3390/cancers16112030 · Cited by 62
“Nanocarriers decorated with modified ligands that target T cell receptors and co-stimulating molecules, such as CD3 and CD28, enable specific delivery of their contents [51].”
Background
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Halabitska, I., Бабинец, Л. С., Oksenych, V., & Kamyshnyi, O. (2024) · Biomedicines · doi:10.3390/biomedicines12081630 · Cited by 57
“TCR engagement triggers intracellular signaling via the ERK/MAPK pathways, while CD28 signaling activates the PI3K-Akt-mTOR pathway [131,132].”
Background
Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?
Wong, Y. C., Tay, S. S., McCaughan, G. W., Bowen, D. G., & Bertolino, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.033 · Cited by 58
Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells
Relation, T., Dominici, M., & Horwitz, E. M. (2017) · Stem Cells · doi:10.1002/stem.2596 · Cited by 55
Vaccine therapy in hematologic malignancies
Avigan, D., & Rosenblatt, J. M. (2018) · Blood · doi:10.1182/blood-2017-11-785873 · Cited by 53
Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
Fujita, Y., Tinoco, R., Li, Y., Senft, D., & Ronai, Z. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.002 · Cited by 55
Applications of Biomaterials for Immunosuppression in Tissue Repair and Regeneration
Shen, P. F., Chen, Y., Luo, S., Fan, Z., Wang, J., Chang, J., & Deng, J. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.019 · Cited by 56
CAR-modified T-cell therapy for cancer: an updated review
Haji-Fatahaliha, M., Hosseini, M., Akbarian, A., Sadreddini, S., Jadidi‐Niaragh, F., & Yousefi, M. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1052465 · Cited by 54
Renal C3 Complement Component: Feed Forward to Diabetic Kidney Disease
Kelly, K. J., Liu, Y., Zhang, J., & Dominguez, J. H. (2015) · American Journal of Nephrology · doi:10.1159/000371426 · Cited by 54
Emerging Co-signaling Networks in T Cell Immune Regulation
Jung, K., & Choi, I. (2013) · Immune Network · doi:10.4110/in.2013.13.5.184 · Cited by 54
Immune checkpoint inhibitors: a patent review (2010-2015)
Collin, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1176150 · Cited by 54
Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity
Pérez-Sotelo, D., Roca-Rivada, A., Larrosa-García, M., Castelao, C., de la Torre, I. B., Baltar, J., Crujeiras, A. B., Seoane, L. M., Casanueva, F. F., & Pardo, M. (2016) · Endocrine · doi:10.1007/s12020-016-1132-1 · Cited by 54
T-cell stimuli independently sum to regulate an inherited clonal division fate
Marchingo, J. M., Prevedello, G., Kan, A., Heinzel, S., Hodgkin, P. D., & Duffy, K. R. (2016) · Nature Communications · doi:10.1038/ncomms13540 · Cited by 53
Elevated T cell activation score is associated with improved survival of breast cancer
Lu, L., Bai, Y., & Wang, Z. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4281-x · Cited by 55
Immune checkpoint inhibitors
Hui, E. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201810035 · Cited by 54
Methylation of immune synapse genes modulates tumor immunogenicity
Berglund, A., Mills, M. N., Putney, R. M., Hamaidi, I., Mulé, J. J., & Kim, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131234 · Cited by 54
The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness
Wang, Z., Guo, X., Gao, L., Deng, K., Lian, W., Bao, X., Feng, M., Duan, L., Zhu, H., & Xing, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa449 · Cited by 54
Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
The role of P-selectin in cancer-associated thrombosis and beyond
Yeini, E., & Satchi‐Fainaro, R. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.027 · Cited by 53
Clinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54
“T cells represent indispensable components of the human immune system, regulated by costimulatory and inhibitory signals as they engage in the recognition and elimination of tumor cells in vivo [7, 8].”
Background
IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response
Zhang, J., Feng, H., Zhao, J., Feldman, E. R., Chen, S., Yuan, W., Huang, C., Akbari, O., Tibbetts, S. A., & Feng, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.083 · Cited by 52
Pathogenesis of Peripheral T Cell Lymphoma
Pizzi, M., Margolskee, E. M., & Inghirami, G. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043821 · Cited by 55
CD96 expression determines the inflammatory potential of IL-9–producing Th9 cells
Stanko, K., Iwert, C., Appelt, C., Vogt, K., Schumann, J., Strunk, F. J., Ahrlich, S., Schlickeiser, S., Romagnani, C., Jürchott, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708329115 · Cited by 51
Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1669-y · Cited by 53
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
Liu, Y. L., & Zamarin, D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0740-8 · Cited by 53
CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Zhang, H., Watanabe, R., Berry, G. J., Nadler, S. G., Goronzy, J. J., & Weyand, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.049 · Cited by 53
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells
Bai, Z., Lundh, S. M., Kim, D., Woodhouse, S., Barrett, D. M., Myers, R. M., Grupp, S. A., Maus, M. V., June, C. H., Cámara, P. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002328 · Cited by 57
Activation pathways that drive CD4 + T cells to break tolerance in autoimmune diseases*
Krovi, S. H., & Kuchroo, V. K. (2022) · Immunological Reviews · doi:10.1111/imr.13071 · Cited by 56
Manipulation of Multiple Cell–Cell Interactions by Tunable DNA Scaffold Networks
Guo, Z., Zhang, L., Yang, Q., Peng, R., Yuan, X., Xu, L., Wang, Z., Chen, F., Huang, H., Liu, Q., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202111151 · Cited by 52
Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents
Diamanti, A. P., Rosado, M. M., Scarsella, M., Germano, V., Giorda, E., Cascioli, S., Laganà, B., D’Amelio, R., & Carsetti, R. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12367 · Cited by 52
The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
Nelson, D. J., Fisher, S. A., & Robinson, B. W. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/789069 · Cited by 52
IFNγ-Dependent Interactions between ICAM-1 and LFA-1 Counteract Prostaglandin E2–Mediated Inhibition of Antitumor CTL Responses
Basingab, F. S., Ahmadi, M., & Morgan, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0146 · Cited by 52

Authors: Chen, L., & Flies, D. B.
Affiliations: Yale Cancer Center (US)
University of New Mexico (US)
Corresponding author: Chen, Lieping
ORCID: Chen, Lieping
Flies, Dallas B.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-03-08
Volume: 13
Issue: 4
Pages: 227-242
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3405
PMC: PMC3786574
OpenAlex: W2130473166
Cited by: 3,114
References: 135
Citations by year: 2026: 148 · 2025: 258 · 2024: 259 · 2023: 276 · 2022: 305 · 2021: 312 · 2020: 310 · 2019: 250 · 2018: 275 · 2017: 238 · 2016: 195 · 2015: 148 · 2014: 101 · 2013: 35
FWCI: 13.52
Type: journal article
Language: en
Update notices: erratum (2013-06-05)
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Melanoma Research Alliance
National Cancer Institute (CA 97085, CA 16359, CA121974, CA86721, R01CA097085, CA142779, R01CA085721, R01CA142779, P50CA121974, P30CA016359)
National Institute of Allergy and Infectious Diseases (T32AI089704, R01AI072592, AI72592, T32AI007247)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell costimulation, T cell co-inhibition, costimulatory receptors, co-inhibitory receptors, T cell receptor signaling, T cell activation, T cell differentiation, immune checkpoint molecules
MeSH terms: Humans, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Signal Transduction, CD28 Antigens, B7-1 Antigen, Models, Immunological, B7-2 Antigen, Receptors, Tumor Necrosis Factor, Member 14

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular mechanisms of T cell co-stimulation and co-inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks